Ocugen (OCGN) EBITDA (2014 - 2026)
Ocugen's (OCGN) quarterly EBITDA came in at -$17.8 million in Q1 2026, down 23.02% YoY from -$23.2 million in Q1 2025, and down 4.97% on a QoQ basis from -$17.0 million in Q4 2025.
Ocugen (OCGN) EBITDA (2014 - 2026) Analysis & Trends
Ocugen (OCGN) has 13 years of EBITDA data on file, last reported at -$17.8 million in Q1 2026.
- Quarterly EBITDA fell 23.02% year-over-year to -$17.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$66.3 million (down 16.15% YoY) and the FY2025 annual result came in at -$62.9 million, down 14.9% from the prior year.
- EBITDA retreated to -$17.8 million in Q1 2026, from -$17.0 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$11.5 million in Q4 2023 to a low of -$25.1 million in Q3 2022.
- A 5-year average of -$17.1 million and a median of -$17.0 million in 2025 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2022 — EBITDA slumped 169.66% — and 2023, when it surged 50.65%.
- Tracing OCGN's EBITDA over 5 years: stood at -$23.4 million in 2022, then soared by 50.65% to -$11.5 million in 2023, then declined by 20.09% to -$13.8 million in 2024, then decreased by 22.8% to -$17.0 million in 2025, then slipped by 4.97% to -$17.8 million in 2026.
- The last three EBITDA figures came in at -$17.8 million (Q1 2026), -$17.0 million (Q4 2025), and -$17.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Ocugen | 457.71 Mn | 357.61 Mn | - | -16.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.44 Mn |
| Mar 31, 2026 | -17.84 Mn |
| Dec 31, 2025 | -17.00 Mn |
| Sep 30, 2025 | -17.63 Mn |
| Jun 30, 2025 | -13.80 Mn |
| Mar 31, 2025 | -14.50 Mn |
| Dec 31, 2024 | -13.84 Mn |
| Sep 30, 2024 | -13.25 Mn |
| Jun 30, 2024 | -15.45 Mn |
| Mar 31, 2024 | -12.22 Mn |
| Dec 31, 2023 | -11.53 Mn |
| Sep 30, 2023 | -12.43 Mn |
| Jun 30, 2023 | -23.54 Mn |
| Mar 31, 2023 | -18.04 Mn |
| Dec 31, 2022 | -23.36 Mn |
| Sep 30, 2022 | -25.11 Mn |
| Jun 30, 2022 | -21.58 Mn |
| Mar 31, 2022 | -19.03 Mn |
| Dec 31, 2021 | -14.57 Mn |
| Sep 30, 2021 | -10.79 Mn |